Table 1.
Baseline characteristics of prostate cancer patients prescribed degarelix, leuprorelin, goserelin, or triptorelin in a UK population-based cohort study (n = 9081)
| Baseline characteristicsa | Degarelix users n = 101 | Leuprorelin users n = 3289 | Goserelin users n = 4366 | Triptorelin users n = 1325 |
|---|---|---|---|---|
| Age, year | n = 100 | n = 3276 | n = 4366 | n = 1325 |
| Mean (SD) | 74.8 (9.0) | 75.9 (8.6) | 74.0 (8.5) | 75.3 (8.3) |
| BMI, kg/m2, n (%) | n = 93 | n = 3091 | n = 4012 | n = 1207 |
| Mean (SD) | 26.9 (5.0) | 27.4 (4.9) | 27.5 (4.5) | 27.3 (4.5) |
| Overweight: 25–30 | 39 (41.9) | 1364 (44.1) | 1836 (45.8) | 548 (45.4) |
| Obese: > 30 | 21 (22.6) | 745 (24.1) | 993 (24.7) | 295 (24.4) |
| Smoking status, n (%) | n = 97 | n = 3162 | n = 4103 | n = 1258 |
| Current smoker | 9 (9.3) | 278 (8.8) | 458 (11.2) | 146 (11.6) |
| Ex-smoker | 49 (50.5) | 1464 (46.3) | 1858 (45.3) | 567 (45.1) |
| PSA, ng/ml, closest to baseline, n (%) | n = 67 | n = 2663 | n = 3260 | n = 1115 |
| Median (IQR) | 72.4 (3.7–273.0) | 10.0 (1.4–36.7) | 8.0 (0.8–24.9) | 10.6 (1.6–36.4) |
| < 20 | 27 (40.3) | 1727 (64.9) | 2312 (70.9) | 694 (62.2) |
| ≥ 20 | 40 (59.7) | 936 (35.1) | 948 (29.1) | 421 (37.8) |
| Testosterone, ng/ml | n = 5 | n = 240 | n = 324 | n = 91 |
| Mean (SD) | 14.7 (4.9) | 16.2 (18.4) | 13.8 (13.8) | 15.4 (15.1) |
| Comorbidity ever before/at baseline, n (%) | ||||
| Cardiovascular disease | 38 (37.6) | 1075 (32.7) | 1288 (29.5) | 385 (29.1) |
| IHD | 22 (21.8) | 639 (19.4) | 822 (18.8) | 213 (16.1) |
| HF | 4 (4.0) | 168 (5.1) | 154 (3.5) | 53 (4.0) |
| MI | 15 (14.8) | 324 (9.8) | 420 (9.6) | 88 (6.6) |
| Arrhythmia | 20 (19.8) | 615 (18.7) | 669 (15.3) | 222 (16.7) |
| Chronic kidney disease | 13 (12.9) | 524 (15.9) | 598 (13.7) | 208 (15.7) |
| Hepatic impairment | 2 (2.0) | 85 (2.6) | 121 (2.8) | 39 (2.9) |
| Osteoporosis | 2 (2.0) | 64 (1.9) | 94 (2.1) | 21 (1.6) |
| Urticaria | 2 (2.0) | 88 (2.7) | 152 (3.5) | 30 (2.3) |
| UTIs | ||||
| 1 | 9 (8.9) | 169 (5.1) | 229 (5.3) | 65 (4.9) |
| 2 | 2 (2.0) | 25 (0.8) | 54 (1.2) | |
| > 2 | 0 (0) | 26 (0.8) | 19 (0.4) | 5 (0.4) |
| Diabetes mellitus | 19 (18.8) | 532 (16.2) | 704 (16.1) | 213 (16.1) |
| Drug use 6 months before/at baseline, n (%) | ||||
| Antithrombotic treatment | 50 (49.5) | 1297 (39.4) | 1676 (38.4) | 520 (39.2) |
| Anti-androgens | 10 (9.9) | 1185 (36.0) | 1521 (34.8) | 612 (46.2) |
BMI body mass index, HF heart failure, IHD ischaemic heart disease, IQR interquartile range, MI myocardial infarction, PSA prostate-specific antigen, SD standard deviation, UTI urinary tract infection
aClosest to baseline for: age, sex, BMI, smoking status, PSA, testosterone; ever before baseline: comorbidity